A first-of-its-kind study discovered that women and minorities who underwent a percutaneous coronary intervention (PCI) are at greater risk of experiencing recurrent cardiac events within the first year after their procedure compared to Caucasian men. Those outcomes may be attributable to their race, gender and socioeconomic status rather than the PCI procedure itself. Results from “Interaction Effects of Race/Ethnicity and Sex on Outcomes after PCI: A Subanalysis of the PLATINUM Diversity study” were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions May 10-13 in New Orleans.

HRS released a consensus statement on MRI for patients with cardiac implantable electronic devices

May 15, 2017 — The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement in the United States on indications of patients who undergo magnetic resonance imaging (MRI) and radiation exposure with cardiovascular implantable electronic devices (CIEDs). The expert writing group presented the recommendations included in the “2017 HRS Expert Consensus Statement on Magnetic Resonance Imaging and Radiation Exposure in Patients with Cardiovascular Implantable Electronic Devices” at Heart Rhythm 2017, the Heart Rhythm Society’s 38th Annual Scientific Sessions.

For patients who undergo transcatheter aortic valve replacement (TAVR), their risk factors, not the type of valve used, determined their 30-day post-TAVR outcomes. Results from “Impact of valve design and bivalirudin vs. unfractionated heparin for anticoagulation in transcatheter aortic valve replacement: Results from the BRAVO-3 trial” were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.

In a large-scale analysis of percutaneous coronary intervention (PCI)-related hospitalizations, people admitted to the hospital on a weekend were twice more likely to die than those hospitalized on a weekday. Results from “Weekend Effect for Percutaneous Coronary Intervention Admissions: A 10-Year U.S. Experience” were presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.

May 15, 2017 – The U.S. Food and Drug Administration (FDA) has granted market clearance Medtronic’s portfolio of quadripolar cardiac resynchronization therapy-pacemakers (CRT-Ps) that improve therapy delivery for patients with heart failure. These devices also allow patients to receive MRI (magnetic resonance imaging) scans in either 1.5 or 3 Tesla (T) machines.

A study in 65 countries has revealed low adoption of International Atomic Energy Agency (IAEA) recommendations to reduce nuclear cardiology radiation exposure. The research was presented at ICNC 2017, May 7-9 in Vienna Austria, by Edward Hulten, M.D., a cardiologist at the Walter Reed National Military Medical Center, Bethesda, Md.

PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and effectiveness of a new stent to treat patients with coronary heart disease who are at higher risk for bleeding.

An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a stem cell therapy (CD34+ cells) to treat patients with refractory angina showed a statistically significant improvement in exercise time as well as a reduction in mortality. Results from “CD34+ Stem Cell Therapy Improves Exercise Time and Mortality in Refractory Angina: A Patient Level Meta-Analysis” were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.

Peripheral artery disease (PAD) patients who were treated with an anti-inflammatory steroid injected directly into the tissue surrounding their leg artery showed a significant reduction in inflammatory biomarkers, according to new data from the DANCE trial. Results from the trial were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.

More than one-third of patients undergoing transcatheter aortic valve replacement (TAVR) were observed to have atrial fibrillation (AF) either at baseline or new-onset within 30 days after TAVR, according to data from the BRAVO-3 randomized trial. Patients with new-onset AF had a greater than 4-fold greater risk of stroke within 30 days. Results from the trial were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now